Your browser doesn't support javascript.
loading
Global burden of gynaecological cancers in 2022 and projections to 2050.
Zhu, Binhua; Gu, Hao; Mao, Zhihan; Beeraka, Narasimha M; Zhao, Xiang; Anand, Mahesh Padukudru; Zheng, Yufei; Zhao, Ruiwen; Li, Siting; Manogaran, Prasath; Fan, Ruitai; Nikolenko, Vladimir N; Wen, Haixiao; Basappa, Basappa; Liu, Junqi.
Afiliação
  • Zhu B; Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Gu H; Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Mao Z; Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Beeraka NM; Henan Medical College, Zhengzhou University, Zhengzhou, China.
  • Zhao X; Raghavendra Institute of Pharmaceutical Education and Research (RIPER), Anantapuramu, Chiyyedu, Andhra Pradesh, India.
  • Anand MP; Herman B. Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Zheng Y; Department of Human Anatomy and Histology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.
  • Zhao R; Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Li S; Department of Pulmonary Medicine, JSS Medical College, JSS Academy of Higher Education & Research (JSS AHER), Mysuru, Karnataka, India.
  • Manogaran P; Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Fan R; Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Nikolenko VN; Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Wen H; Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Basappa B; Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Liu J; Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
J Glob Health ; 14: 04155, 2024 Aug 16.
Article em En | MEDLINE | ID: mdl-39148469
ABSTRACT

Background:

The incidence and mortality of gynaecological cancers can significantly impact women's quality of life and increase the health care burden for organisations globally. The objective of this study was to evaluate global inequalities in the incidence and mortality of gynaecological cancers in 2022, based on The Global Cancer Observatory (GLOBOCAN) 2022 estimates. The future burden of gynaecological cancers (GCs) in 2050 was also projected.

Methods:

Data regarding to the total cases and deaths related to gynaecological cancer, as well as cases and deaths pertaining to different subtypes of GCs, gathered from the GLOBOCAN database for the year 2022. Predictions for the number of cases and deaths in the year 2050 were derived from global demographic projections, categorised by world region and Human Development Index (HDI).

Results:

In 2022, there were 1 473 427 new cases of GCs and 680 372 deaths. The incidence of gynecological cancer reached 30.3 per 100 000, and the mortality rate hit 13.2 per 100 000. The age-standardised incidence of GCs in Eastern Africa is higher than 50 per 100 000, whereas the age-standardised incidence in Northern Africa is 17.1 per 100 000. The highest mortality rates were found in East Africa (ASMR (age-standardised mortality rates) of 35.3 per 100 000) and the lowest in Australia and New Zealand (ASMR of 8.1 per 100 000). These are related to the endemic areas of HIV and HPV. Very High HDI countries had the highest incidence of GCs, with ASIR (age-standardised incidence rates) of 34.8 per 100 000, and low HDI countries had the second highest incidence rate, with an ASIR of 33.0 per 100 000. Eswatini had the highest incidence and mortality (105.4 per 100 000; 71.1 per 100 000) and Yemen the lowest (5.8 per 100 000; 4.4 per 100 000). If the current trends in morbidity and mortality are maintained, number of new cases and deaths from female reproductive tract tumours is projected to increase over the next two decades.

Conclusions:

In 2022, gynaecological cancers accounted for 1 473 427 new cases and 680 372 deaths globally, with significant regional disparities in incidence and mortality rates. The highest rates were observed in Eastern Africa and countries with very high and low HDI, with Eswatini recording the most severe statistics. If current trends continue, the number of new cases and deaths from gynaecological cancers is expected to rise over the next two decades, highlighting the urgent need for effective interventions.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Saúde Global / Neoplasias dos Genitais Femininos Limite: Female / Humans Idioma: En Revista: J Glob Health Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Saúde Global / Neoplasias dos Genitais Femininos Limite: Female / Humans Idioma: En Revista: J Glob Health Ano de publicação: 2024 Tipo de documento: Article